159 related articles for article (PubMed ID: 36436416)
21. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.
Sabha N; Knobbe CB; Maganti M; Al Omar S; Bernstein M; Cairns R; Çako B; von Deimling A; Capper D; Mak TW; Kiehl TR; Carvalho P; Garrett E; Perry A; Zadeh G; Guha A; Sidney Croul
Neuro Oncol; 2014 Jul; 16(7):914-23. PubMed ID: 24470545
[TBL] [Abstract][Full Text] [Related]
22. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH
Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906
[TBL] [Abstract][Full Text] [Related]
23. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
24. Integrated analysis of the genomic and transcriptional profile of gliomas with isocitrate dehydrogenase-1 and tumor protein 53 mutations.
Liu HQ; Li WX; An YW; Wu T; Jiang GY; Dong Y; Chen WX; Wang JC; Wang C; Song S
Int J Immunopathol Pharmacol; 2022; 36():3946320221139262. PubMed ID: 36377597
[No Abstract] [Full Text] [Related]
25. IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas.
Shibahara I; Sonoda Y; Kanamori M; Saito R; Yamashita Y; Kumabe T; Watanabe M; Suzuki H; Kato S; Ishioka C; Tominaga T
Int J Clin Oncol; 2012 Dec; 17(6):551-61. PubMed ID: 21971842
[TBL] [Abstract][Full Text] [Related]
26. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
[TBL] [Abstract][Full Text] [Related]
28. MRI features predict survival and molecular markers in diffuse lower-grade gliomas.
Zhou H; Vallières M; Bai HX; Su C; Tang H; Oldridge D; Zhang Z; Xiao B; Liao W; Tao Y; Zhou J; Zhang P; Yang L
Neuro Oncol; 2017 Jun; 19(6):862-870. PubMed ID: 28339588
[TBL] [Abstract][Full Text] [Related]
29. Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses.
Cheng W; Ren X; Zhang C; Cai J; Han S; Wu A
Mol Neurobiol; 2017 Oct; 54(8):5996-6005. PubMed ID: 27696222
[TBL] [Abstract][Full Text] [Related]
30. Identification of potential biomarkers related to glioma survival by gene expression profile analysis.
Hsu JB; Chang TH; Lee GA; Lee TY; Chen CY
BMC Med Genomics; 2019 Mar; 11(Suppl 7):34. PubMed ID: 30894197
[TBL] [Abstract][Full Text] [Related]
31. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
32. Analysis of isocitrate dehydrogenase 1 mutation in 97 patients with glioma.
Zhou YX; Wang JX; Feng M; Sun CM; Sun T; Chen GL; Du ZW
J Mol Neurosci; 2012 Jul; 47(3):442-7. PubMed ID: 22113362
[TBL] [Abstract][Full Text] [Related]
33. Whole-Tumor Histogram and Texture Analyses of DTI for Evaluation of
Park YW; Han K; Ahn SS; Choi YS; Chang JH; Kim SH; Kang SG; Kim EH; Lee SK
AJNR Am J Neuroradiol; 2018 Apr; 39(4):693-698. PubMed ID: 29519794
[TBL] [Abstract][Full Text] [Related]
34. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
[TBL] [Abstract][Full Text] [Related]
35. Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.
Hersh DS; Peng S; Dancy JG; Galisteo R; Eschbacher JM; Castellani RJ; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
J Neurooncol; 2018 Jun; 138(2):241-250. PubMed ID: 29453678
[TBL] [Abstract][Full Text] [Related]
36. Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas.
Yi L; Fan X; Li J; Yuan F; Zhao J; Nistér M; Yang X
Aging (Albany NY); 2021 Jan; 13(3):3645-3660. PubMed ID: 33493139
[TBL] [Abstract][Full Text] [Related]
37. Expression and Prognostic Role of PANK1 in Glioma.
Zhao Z; Xu X; Ma S; Li L
Comb Chem High Throughput Screen; 2024; 27(5):715-724. PubMed ID: 37138430
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
[TBL] [Abstract][Full Text] [Related]
39. High-grade gliomas with isocitrate dehydrogenase wild-type and 1p/19q codeleted: Atypical molecular phenotype and current challenges in molecular diagnosis.
Zheng L; Zhang M; Hou J; Gong J; Nie L; Chen X; Zhou Q; Chen N
Neuropathology; 2020 Dec; 40(6):599-605. PubMed ID: 32761642
[TBL] [Abstract][Full Text] [Related]
40. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
Aoki K; Nakamura H; Suzuki H; Matsuo K; Kataoka K; Shimamura T; Motomura K; Ohka F; Shiina S; Yamamoto T; Nagata Y; Yoshizato T; Mizoguchi M; Abe T; Momii Y; Muragaki Y; Watanabe R; Ito I; Sanada M; Yajima H; Morita N; Takeuchi I; Miyano S; Wakabayashi T; Ogawa S; Natsume A
Neuro Oncol; 2018 Jan; 20(1):66-77. PubMed ID: 29016839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
